Upgrade to SI Premium - Free Trial

Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)

March 16, 2026 8:41 AM
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $41.00 price target on Teva Pharma (NYSE: TEVA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments